Escalated as Compared with Standard Doses of Doxorubicin in BACOP Therapy for Patients with Non-Hodgkin's Lymphoma - Concepedia

Concepedia

Publication | Closed Access

Escalated as Compared with Standard Doses of Doxorubicin in BACOP Therapy for Patients with Non-Hodgkin's Lymphoma

63

Citations

24

References

1993

Year

Ralph M. Meyer, Ian Quirt, Jamey Skillings, M. Christine Cripps, Vivien Bramwell, Brian Weinerman, Mary Gospodarowicz, Bruce F. Burns, Ann Marie Sargeant, Lois E. Shepherd,

New England Journal of Medicine

Abstract

In patients with advanced-stage intermediate- or high-grade non-Hodgkin's lymphoma, escalating the dose of doxorubicin in the BACOP regimen increases toxicity but does not improve the rate of response or survival.

References

	Year	Citations

Page 1